Choreo LLC Acquires New Holdings in Atrion Co. (NASDAQ:ATRI)

Choreo LLC bought a new stake in Atrion Co. (NASDAQ:ATRI) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 867 shares of the medical instruments supplier’s stock, valued at approximately $392,000.

Several other large investors also recently added to or reduced their stakes in ATRI. BNP Paribas Financial Markets lifted its stake in shares of Atrion by 3.6% in the 1st quarter. BNP Paribas Financial Markets now owns 723 shares of the medical instruments supplier’s stock valued at $335,000 after purchasing an additional 25 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of Atrion by 12.7% in the second quarter. Principal Financial Group Inc. now owns 681 shares of the medical instruments supplier’s stock worth $308,000 after buying an additional 77 shares during the last quarter. Quadrant Capital Group LLC bought a new stake in shares of Atrion during the 4th quarter worth about $36,000. Oppenheimer Asset Management Inc. increased its holdings in shares of Atrion by 12.0% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 1,105 shares of the medical instruments supplier’s stock valued at $512,000 after acquiring an additional 118 shares during the last quarter. Finally, Comerica Bank raised its stake in shares of Atrion by 60.9% in the 1st quarter. Comerica Bank now owns 415 shares of the medical instruments supplier’s stock valued at $192,000 after acquiring an additional 157 shares in the last quarter. 66.19% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Atrion in a report on Wednesday, September 11th. They set a “sell” rating on the stock.

Atrion Price Performance

Atrion stock opened at $459.92 on Tuesday. Atrion Co. has a fifty-two week low of $274.98 and a fifty-two week high of $503.24. The firm has a fifty day moving average price of $458.42 and a two-hundred day moving average price of $443.19. The firm has a market cap of $809.46 million, a price-to-earnings ratio of 43.23 and a beta of 0.69.

Atrion (NASDAQ:ATRI) last posted its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.23 earnings per share for the quarter. The business had revenue of $48.77 million during the quarter. Atrion had a return on equity of 7.75% and a net margin of 10.60%.

Atrion Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.